In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. e16693-e16693
Abstract:
e16693 Background: Insulin-like growth factors I and II (IGF-I and II), transforming growth factor β (TGFβ) and its receptor (TGFβR2) are involved in cancer pathogenesis. At the same time, the features of these parameters in the blood related to the disease nature have yet to be determined. The purpose of the study was to analyze the dynamics of IGF-I, IGF-II, TGFβ and TGFβR2 in the blood of patients with pancreatic cancer. Methods: The study included male patients with pancreatic adenocarcinoma T 1-3 N 0-1 M 0 (A, n = 18), pancreatic neuroendocrine tumors (NET, n = 12) and pancreatic adenocarcinoma with the neuroendocrine component T 1-3 N 0-1 M 0 (A+NEC, n = 12) before the treatment. Healthy males (n = 21) were controls. Blood levels of IGF-I and IGF-II were measured by ELISA using standard test systems (Meddiagnost, Germany), as well as levels of TGFβ (BenderMedSystem, Austria) and TGFβR2 (RayBiotech, USA). Results: Patients with pancreatic cancer showed increased blood levels of IGF-II: in PA – by 1.9 times (p˂0.05), in NET – by 2.7 times and in A+NEC – by 3.4 times compared to values in healthy donors. TGFβ was elevated only in patients with A by 1.5 times (p˂0.05). TGFβR2 in the blood of patients with NET and A+NEC was increased by 4.8 and 4.5 times respectively, while in patients with A it was similar to control values. The TGFβ/TGFβR2 ratio was calculated; A+NEC was prognosed in patients with its level of 1.32±0.2. Conclusions: High blood levels of IGF-II were registered in patients with pancreatic cancer. The TGFβ/TGFβR2 ratio served as informative laboratory tests to predict the nature of pancreatic disease.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2020.38.15_suppl.e16693
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2020
detail.hit.zdb_id:
2005181-5